BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16084870)

  • 1. Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists.
    Chung K; Krey L; Katz J; Noyes N
    Fertil Steril; 2005 Aug; 84(2):313-8. PubMed ID: 16084870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation.
    Malmusi S; La Marca A; Giulini S; Xella S; Tagliasacchi D; Marsella T; Volpe A
    Fertil Steril; 2005 Aug; 84(2):402-6. PubMed ID: 16084881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
    Berin I; Stein DE; Keltz MD
    Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of gonadotropin-releasing hormone antagonists in poor responders.
    Mahutte NG; Arici A
    Fertil Steril; 2007 Feb; 87(2):241-9. PubMed ID: 17113088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study.
    Schachter M; Friedler S; Ron-El R; Zimmerman AL; Strassburger D; Bern O; Raziel A
    Fertil Steril; 2008 Oct; 90(4):1087-93. PubMed ID: 18023439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles.
    Dovey S; McIntyre K; Jacobson D; Catov J; Wakim A
    Fertil Steril; 2011 Sep; 96(3):585-9. PubMed ID: 21774931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are gonadotropin-releasing hormone agonists losing popularity? Current trends at a large fertility center.
    Reh A; Krey L; Noyes N
    Fertil Steril; 2010 Jan; 93(1):101-8. PubMed ID: 18973891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years.
    D'Amato G; Caroppo E; Pasquadibisceglie A; Carone D; Vitti A; Vizziello GM
    Fertil Steril; 2004 Jun; 81(6):1572-7. PubMed ID: 15193479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure.
    Fisch JD; Keskintepe L; Sher G
    Fertil Steril; 2008 Feb; 89(2):342-7. PubMed ID: 17562336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.
    Merviel P; Antoine JM; Mathieu E; Millot F; Mandelbaum J; Uzan S
    Fertil Steril; 2004 Jul; 82(1):119-25. PubMed ID: 15236999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of different stimulation protocols efficacy in poor responders undergoing IVF: a retrospective study.
    Madani T; Ashrafi M; Yeganeh LM
    Gynecol Endocrinol; 2012 Feb; 28(2):102-5. PubMed ID: 22263965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures.
    Ruvolo G; Bosco L; Pane A; Morici G; Cittadini E; Roccheri MC
    Fertil Steril; 2007 Mar; 87(3):542-6. PubMed ID: 17126339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
    Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
    Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.